Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Oncology Sales Drive Strong Quarter For Genentech

11 Oct 2005

• By Mary Bruce

Avastin and Herceptin were each up more than 70% over the prior year’s quarter.

Related Content

Avastin Pricing Strategy, Expanded Indications Under Review At Genentech

18 Jul 2005

Genentech/Biogen Idec Submit Rituxan sBLA For Rheumatoid Arthritis

31 Aug 2005

Genentech Plans Herceptin Early-Stage Breast Cancer Submission

17 May 2005

Genentech/OSI Raise Tarceva Price 15% In Wake Of Iressa Failure

12 Apr 2005

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.